Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
暂无分享,去创建一个
Hiroshi Onishi | Tsutomu Araki | T. Araki | H. Onishi | Atsushi Nambu | A. Nambu | Yoko Satoh | Y. Satoh
[1] C. Rübe,et al. Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[2] Hiroki Shirato,et al. STEREOTACTIC RADIATION THERAPY WORKSHOP Hypofractionated Stereotactic Radiotherapy (HypoFXSRT) for Stage I Non-small Cell Lung Cancer: Updated Results of 257 Patients in a Japanese Multi-institutional Study , 2007 .
[3] Kyoungjune Pak,et al. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer , 2012, Nuclear medicine communications.
[4] T. Araki,et al. Stereotactic hypofractionated high‐dose irradiation for stage I nonsmall cell lung carcinoma , 2004, Cancer.
[5] B. Loo,et al. Metabolic imaging metrics correlate with survival in early stage lung cancer treated with stereotactic ablative radiotherapy. , 2012, Lung cancer.
[6] Brit B. Turnbull,et al. Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. , 2008, International journal of radiation oncology, biology, physics.
[7] Quynh-Thu Le,et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. , 2007, International journal of radiation oncology, biology, physics.
[8] Peter Balter,et al. Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer , 2012, Radiation oncology.
[9] Hiroshi Onishi,et al. A new irradiation system for lung cancer combining linear accelerator, computed tomography, patient self-breath-holding, and patient-directed beam-control without respiratory monitoring devices. , 2003, International journal of radiation oncology, biology, physics.
[10] John Cho,et al. Stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC): is FDG-PET a predictor of outcome? , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[11] R. Timmerman,et al. FDG-PET and stereotactic body radiotherapy (SBRT) for stage I non-small-cell lung cancer , 2007 .
[12] T. Araki,et al. Value of dual time point F-18 FDG-PET/CT imaging for the evaluation of prognosis and risk factors for recurrence in patients with stage I non-small cell lung cancer treated with stereotactic body radiation therapy. , 2012, European journal of radiology.
[13] S. Hyun,et al. Volume-Based Parameters of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Improve Outcome Prediction in Early-Stage Non–Small Cell Lung Cancer After Surgical Resection , 2013, Annals of surgery.
[14] M. Beland,et al. Primary non-small cell lung cancer: review of frequency, location, and time of recurrence after radiofrequency ablation. , 2010, Radiology.
[15] C. Reddy,et al. Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.
[16] Jeon Yeob Jang,et al. Metabolic Tumor Volume of [18F]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Predicts Short-Term Outcome to Radiotherapy With or Without Chemotherapy in Pharyngeal Cancer , 2009, Clinical Cancer Research.
[17] B. Campbell,et al. Clinical outcomes of patients receiving integrated PET/CT-guided radiotherapy for head and neck carcinoma. , 2008, International journal of radiation oncology, biology, physics.